CCL

Összesen 257 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM013562
Első szerző:Abramyuk, Andrij
Cím:Is pre-therapeutical FDG-PET/CT capable to detect high risk tumor subvolumes responsible for local failure in non-small cell lung cancer? / Andrij Abramyuk, Sergey Tokalov, Klaus Zöphel, Arne Koch, Kornelia Szluha Lazanyi, Charles Gillham, Thomas Herrmann, Nasreddin Abolmaali
Dátum:2009
ISSN:0167-8140
Megjegyzések:Local failure is a significant issue following radiotherapy (RT) for patients with non-small cell lung cancer (NSCLC). The aim of this study was to find out whether FDG-PET/CT is capable to predict tumor relapse location in patients with NSCLC, in particular to determine high risk tumors' subvolumes responsible for local failure. Material and methods: Ten patients with locoregional relapse of NSCLC underwent FDG-PET/CT before, during, and in the 4-12 months following curative chemoradiotherapy (ChRT, 66 Gy) using a combined PET/CT scanner. Morphologic and metabolic tumor volumetry and an evaluation of FDG-uptake dynamics were performed. Results: CT showed partial reduction of tumor volume after RT in all patients. PET-revealed partial in eight patients and complete metabolic response in two patients during RT. Six to nine months after RT, local failure was diagnosed in all patients with both methods. Tumor recurrences were localized mostly in the most active ones of pre-therapeutically metabolic regions of the primary tumor. Conclusions: Local failure in NSCLC appears most common at the primary site and within the irradiated target volume with the highest FDG uptake. This observation may be useful for further optimization of radiotherapy of NSCLC, for example, by the application of additional radiation dose to subvolumes of primary tumors with higher FDG uptake.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
FDG-PET/CT
Radiotherapy planning
Non-small-cell lung cancer
külföldön készült közlemény
Megjelenés:Radiotherapy And Oncology. - 91 : 3 (2009), p. 399-404. -
További szerzők:Tokalov, Sergej Zöphel, Klaus Koch, Arne Szluha Kornélia (1955-) (radioterapeuta, radiológus, szülész-nőgyógyász, onkológus) Gillham, Charles Herrmann, Thomas Abolmaali, Nasreddin
Internet cím:Szerző által megadott URL
Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

2.

001-es BibID:BIBFORM038652
Első szerző:Alberth Márta (fogszakorvos)
Cím:Significance of oral Candida infections in children with cancer / Alberth M., Majoros L., Kovalecz G., Borbás E., Szegedi I., Márton I. J., Kiss C.
Dátum:2006
ISSN:1219-4956
Megjegyzések:Candidiasis is common in children with cancer, particularly during periods of severe immunosuppression and neutropenia. Our aim was to study the microbiological changes in the oral cavity of children with newly diagnosed cancer. The study group consisted of 30 consecutive children and adolescents, 16 with acute lymphoblastic leukemia and 14 with solid tumors. Oral cultures to detect fungi and bacteria were conducted for all patients before treatment, during and after neutropenic episodes. In 23 patients developing fever simultaneous throat, urine and blood sampling was carried out. No pathogens were found in the cultures taken before the outset (30 cultures) or after recovery from (30 cultures) the neutropenic episodes. In the 45 oral cultures taken during the neutropenic episodes 38 (84.4%) proved positive. Fungi were the most frequently isolated oral pathogens: 33/38 yeast and 6/38 bacterial infections were identified. There was no association between the underlying malignancy and the occurrence of the positive cultures. Of the 30 patients, all 23 (76.7%) who have developed moderate-to-severe neutropenia, developed oral fungal colonization or clinically obvious fungal infection at least on one occasion during the study. In addition to oral samples, fungi were identified in 9/23 pharyngeal swabs, 6/23 urine and 1/23 blood cultures. The initial fungal pathogen was exclusively (33/33) Candida albicans. In extended severe neutropenic states, C. albicans was replaced by non-albicans species (C. kefyr, C. lusitaniae, C. sake, C. tropicalis) in 5 patients between 4 to 6 days of the neutropenic episodes. Four of the nonalbicans Candida strains were resistant to azole-type antifungal agents. Neutropenic episodes of children with cancer are associated with an increased risk of developing oral and even systemic infections with C. albicans that can be replaced by azole-resistant nonalbicans strains in prolonged neutropenia contributing to morbidity of these patients.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Pathology and Oncology Research. - 12 : 4 (2006), p. 237-241. -
További szerzők:Majoros László (1966-) (szakorvos, klinikai mikrobiológus) Kovalecz Gabriella (1973-) (fogszakorvos) Borbás Emese Szegedi István (1969-) (hematológus, onkológus, nefrológus) Márton Ildikó (1954-) (fogszakorvos) Kiss Csongor (1956-) (hematológus, onkológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM029731
Első szerző:Ali, M. J.
Cím:Isolation of drug delivery from drug effect : problems of optimizing drug delivery parameters / Ali M. J., Navalitloha Y., Vavra M. W., Kang E. W., Itskovich A. C., Molnar P., Levy R. M., Groothuis D. R.
Dátum:2006
ISSN:1522-8517
Megjegyzések:A recurring question in the treatment of malignant brain tumors has been whether treatment failure is due to inadequate delivery or ineffective drugs. To isolate these issues, we tested a paradigm in which the "therapeutic" agent was a toxin about which there could be no question of efficacy, provided it was delivered in adequate amounts; we used 10% formalin. We infused 10% formalin into 5- to 8-mm subcutaneous RG-2 and D54-MG gliomas at increasing rates until we achieved 100% tumor cell kill. In RG-2 gliomas, infusions of 10 microl/h x 7 days, and 2, 4, 6, and 8 microl/min x 2 h failed to kill tumors, although growth was delayed, while infusion rates of 12 microl/min x 60 min and 48 microl/min x 15 min produced 100% tumor kill. In D54-MG tumors, infusions of 4, 8, and 24 microl/min produced 100% tumor kill. 14C-Formalin autoradiographs showed a heterogeneous distribution after infusions of 2 microl/min x 2 h, whereas infusions of 48 microl/min x 15 min showed a homogeneous distribution within the tumor, but more than 95% of tissue radioactivity was found in tissue surrounding tumor. Drug delivery remains a major issue in brain tumor treatment: Distribution inhomogeneity, rapid efflux, and consequent treatment failures are likely due to high interstitial fluid pressure. Because the infusion rates being used in the treatment of human brain tumors are low and the tumors are larger, treatment failures can be expected on the basis of inadequate drug delivery alone, regardless of the effectiveness of the drug.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Neuro-Oncology. - 8 : 2 (2006), p. 109-118. -
További szerzők:Navalitloha, Y. Vavra, M. W. Kang, E. W. Itskovich, A. C. Molnár Péter Pál (1951-) (pathológus) Levy, R. M. Groothuis, Dennis
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM081820
035-os BibID:(WOS)000492009300002 (Scopus)85074658973
Első szerző:András Csilla (onkológus szakorvos)
Cím:Retrospective Analysis of Cancer-Associated Myositis Patients over the Past 3 Decades in a Hungarian Myositis Cohort / András Csilla, Bodoki Levente, Nagy-Vincze Melinda, Griger Zoltán, Csiki Emese, Dankó Katalin
Dátum:2020
ISSN:1219-4956 1532-2807
Megjegyzések:Association between cancer and myositis has been extensively reported and malignancy is a potentially life-threating complication in myositis. In this retrospective study authors give an overview of Hungarian cancer-associated myositis (CAM) patients treated at a single centre managing 450 myositis patients. All patients were diagnosed according to Bohan and Peter. Statistical analysis of disease onset, age, sex,muscle, skin and extramuscular symptoms,muscle enzymes, presence of antibodies, treatment and prognosis was performed. 43 patients could be considered as having CAM. 83.72% had cancer within one year of diagnosis of myositis. Most common localizations were ductal carcinoma of breast and adenocarcinoma of lung. Significant differences were observed between CAM and the non-CAM control patients: DM:PM ratio was 2.31:1 vs. 0.87:1, respectively (p = 0.029), age at diagnosis was 56.60 ? 12.79 vs. 38.88 ? 10.88 years, respectively (p < 0.001). Tumour-treatment was the following: surgical removal in 55.81%, chemotherapy in 51.1%, radiotherapy in 39.53%, hormone treatment in 18.6%, combination therapy in 51.16% of patients. Muscle enzyme levels of patients undergoing surgery were significantly reduced after intervention. 36 patients died (83.72%); 25 DM(83.33%) and 11 PM patients (84.62%); 5 years survival was 15.4% for PM and 27.5% for DM. This study demonstrates that DM, distal muscle weakness, asymmetric Raynaud's phenomenon, older age, ANA-negativity are risk factors for developing malignancy and polymyositis patients have less chance of long-lasting survival. It is very important to think about cancer and follow every single myositis patient in the clinical routine because survival rate of CAM is very poor.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Cancer-associatedmyositis (CAM)
Dermatomyositis (DM)
Polymyositis (PM)
Cancer
Muscle weakness
Megjelenés:Pathology & Oncology Research. - 26 : 3 (2020), p. 1749-1755. -
További szerzők:Bodoki Levente (1986-) (PhD hallgató) Nagy-Vincze Melinda (1985-) (orvos) Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Csiki Emese (1986-) (onkoradiológus) Dankó Katalin (1952-2021) (belgyógyász, allergológus és klinikai immunológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM033721
Első szerző:András Csilla (onkológus szakorvos)
Cím:Docetaxel (Taxotere) az emlőrák neoadjuváns kezelésében / András Csilla, Szántó János
Dátum:2002
Tárgyszavak:Orvostudományok Klinikai orvostudományok magyar nyelvű folyóiratközlemény külföldi lapban
egyetemen (Magyarországon) készült közlemény
Megjelenés:Pathology and oncology research. - 8 : Suppl. 2 (2002), p. 11-14. -
További szerzők:Szántó János (1949-) (onkológus szakorvos)
Borító:

6.

001-es BibID:BIBFORM024679
Első szerző:András Csilla (onkológus szakorvos)
Cím:Retrospective Evaluation of 5-fluorouracil-interferon-alfa Treatment of Advanced Colorectal Cancer Patients / Csilla András, Zoltán Csiki, István Gál, István Takács, Lajos Antal, Gyula Szegedi
Dátum:2000
ISSN:1532-2807
Megjegyzések:The authors describe the retrospective analysis of treatment by 5-fluorouracil and interferon-a aof 34 patients with advanced colorectal cancer. An average of 4.6 treatment cycles (3 12) was applied. Complete remission was not observed; partial remission was observed in 8 patients; in 13 patients no change occurred and progression was detected in 14 cases. Remission rate was 22.8%, mean response time was 5.2 (3 12) months, mean progress-free survival 5.6 (0 22) months. Mean survival from the start of treatment was 11.9 (1 42) months and from the establishment of the diagnosis 26.1 (3 60) months. Severe life-threatening side-effects did not occur; other side-effects such as fever, nausea, diarrhea, leucopenia, and anemia responded to drugs. Treatment by 5-FU and interferon, in accordance with other authors findings, improved survival and well-being of patients but no breakthrough has been achieved.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
egyetemen (Magyarországon) készült közlemény
Megjelenés:Pathology and Oncology Research. - 6 : 3 (2000), p. 175-178. -
További szerzők:Csiki Zoltán (1962-) (belgyógyász, allergológus, klinikai immunológus, reumatológus) Gál István (sebész) Takács István (1963-) (sebész) Antal Lajos Szegedi Gyula (1936-2013) (belgyógyász, immunológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Szerző által megadott URL
Borító:

7.

001-es BibID:BIBFORM002881
Első szerző:Andrikovics Hajnalka
Cím:First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts / Andrikovics H., Nahajevszky S., Szilvási A., Bors A., Adám E., Kozma A., Kajtár B., Barta A., Poros A., Tordai A.
Dátum:2007
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Hematological Oncology. - 25 : 3 (2007), p. 143-147. -
További szerzők:Nahajevszky Sarolta Szilvási Anikó (1977-) (molekuláris biológus) Bors András Ádám Emma Kozma András Barta Anikó Poros Anna Tordai Attila Kajtár Béla (1977-) (patológus)
Internet cím:elektronikus változat
DOI
Borító:

8.

001-es BibID:BIBFORM115128
035-os BibID:(cikkazonosító)94 (Scopus)85139253626 (WoS)000861474300001
Első szerző:Awuah, Wireko Andrew
Cím:Exploring the role of Nrf2 signaling in glioblastoma multiforme / Awuah Wireko Andrew, Toufik Abdul-Rahman, Yarlagadda Rohan, Mikhailova Tatiana, Mehta Aashna, Huang Helen, Kundu Mrinmoy, Lopes Leilani, Benson Sylvester, Mykola Lyndin, Vladyslav Sikora, Alexiou Athanasios, Alghamdi Badrah S., Hashem Anwar M., Md Ashraf Ghulam
Dátum:2022
ISSN:2730-6011
Megjegyzések:Glioblastoma multiforme (GBM) is one of the most aggressive glial cell tumors in adults. Although current treatment options for GBM offer some therapeutic benefit, median survival remains poor and does not generally exceed 14 months. Several genes, such as isocitrate dehydrogenase (IDH) enzyme and O6-methylguanine-DNA methyltransferase (MGMT), have been implicated in pathogenesis of the disease. Treatment is often adapted based on the presence of IDH mutations and MGMT promoter methylation status. Recent GBM cell line studies have associated Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) expression with high-grade tumors. Increased Nrf2 expression is often found in tumors with IDH-1 mutations. Nrf2 is an important transcription factor with anti-apoptotic, antioxidative, anti-inflammatory, and proliferative properties due to its complex interactions with multiple regulatory pathways. In addition, evidence suggests that Nrf2 promotes GBM cell survival in hypoxic environment,by up-regulating hypoxia-inducible factor-1 alpha (HIF-1 alpha) and vascular endothelial growth factor (VEGF). Downregulation of Nrf2 has been shown to improve GBM sensitivity to chemotherapy drugs such as Temozolomide. Thus, Nrf2 could be a key regulator of GBM pathways and potential therapeutic target. Further research efforts exploring an interplay between Nrf2 and major molecular signaling mechanisms could offer novel GBM drug candidates with a potential to significantly improve patients prognosis.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Discover Oncology. - 13 : 1 (2022), p. 1-12. -
További szerzők:Abdul-Rahman, Toufik Yarlagadda, Rohan Mikhailova, Tatiana Mehta, Aashna Huang, Helen Kundu, Mrinmoy Lopes, Leilani Benson, Sylvester Mykola, Lyndin Vladyslav, Sikora Alexiou, Athanasios Alghamdi, Badrah S. Hashem, Anwar M. Ashraf, Ghulam Md.
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

9.

001-es BibID:BIBFORM047649
Első szerző:Bácsi Attila (immunológus)
Cím:Colostrinin decreases spontaneous and induced mutation frequencies at the hprt locus in Chinese hamster V79 cells / Attila Bacsi, Leopoldo Aguilera-Aguirre, Peter German, Marian L. Kruzel, Istvan Boldogh
Dátum:2006
Megjegyzések:ColostrininTM (CLN), a uniform mixture of lowmolecular weight, proline-rich polypeptides, induces neurite outgrowth of pheochromocytoma cells, extends the lifespan of diploid fibroblast cells, inhibits beta amyloid-induced apoptosis and resulted in improved cognitive function when administered to Alzheimer's patients. Here we investigated CLN's antimutagenic activity in cells stressed oxidatively or exposed to chemical or physical agents. Our data show that CLN did not alter cell cycle kinetics and cloning efficiency, while it inhibited the development of spontaneous mutations at the coding region of the hypoxanthine phosphoribosyl-transferase (hprt) gene in Chinese hamster V79 cells. In a dosedependent manner, CLN lowered reactive oxygen species (ROS)-induced frequency of cells resistant to 6-thioguanine (6-TG) to nearly background level. Likewise, CLN decreased the frequency of methyl methanesulfonate- or mitomycin C-induced mutations in V79 cells. Notably, CLN (at 100, 250, and 500 ng per ml concentrations) decreased UVAinduced mutation frequency, while only the highest dose of CLN also decreased significantly the number of UVB-induced 6-TG-resistant mutant cells. Similar results were obtained using cell cultures of human origin. Overall, our data show that CLN significantly lowers the mutation frequency that develops spontaneously or is induced by ROS, chemical and physical agents. CLN itself has no mutagenic activity. Therefore, CLN may be used in human therapies systemically and/or locally for the prevention of diseases associated with sequence alterations in genomic and mitochondrial DNA.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
colostrinin
mutation frequency
oxidative stress
genotoxic chemical and physical agents
Megjelenés:Journal of Experimental Therapeutics and Oncology 5 : 4 (2006), p. 249-259. -
További szerzők:Aguilera-Aguirre, Leopoldo Germán Péter (gyermekgyógyász) Kruzel, Marian L. Boldogh István
Internet cím:Szerző által megadott URL
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

10.

001-es BibID:BIBFORM014284
Első szerző:Bai Péter (biokémikus)
Cím:Matrix metalloproteinase activation is an early event in doxorubicin-induced cardiotoxicity / Péter Bai, Jon G. Mabley, Lucas Liaudet, László Virág, Csaba Szabó, Pál Pacher
Dátum:2004
ISSN:0891-5849 (Print)
Megjegyzések:Matrix metalloproteinase (MMP) activation contributes to the development of various pathophysiological conditions, including dilated cardiomyopathy, congestive heart failure, and reperfusion injury. Increased oxidative and nitrosative stress have been implicated in the activation of MMPs and also in the cardiotoxicity of doxorubicin (DOX), a commonly used antitumor agent. Thus, we hypothesized that MMP activation occurs in DOX-induced cardiotoxicity. Male Balb/c mice received a single injection of DOX (25 mg/kg i.p.) and were sacrificed 12 h, 1, 2, 3 and 4 days later. Hearts and aortae were harvested for MMP zymography. DOX induced time-dependent activation of MMPs both in the heart and in the aortic tissue with an earlier onset in the latter. These results demonstrate that MMP activation is an early event in DOX-induced cardiotoxicity and raises the possibility that MMP inhibitors may influence the outcome of this severe complication.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Animals
Antineoplastic Agents/toxicity
Biological Markers/analysis
Cardiomyopathy, Dilated/chemically induced/enzymology
Doxorubicin/ toxicity
Enzyme Activation
Heart/ drug effects
Heart Failure/chemically induced
Male
Matrix Metalloproteinases/ metabolism0891-5849
Mice
Mice, Inbred BALB C
Models, Animal
Myocardium/enzymology/ pathology
Reperfusion Injury/chemically induced/enzymology
Acute Disease
Catalysis/drug effects
Chronic Disease
Creatine Kinase/blood
Disease Models, Animal
Enzyme Inhibitors/pharmacology
Heart/ drug effects/physiopathology
Heart Failure/ chemically induced/physiopathology/prevention & control
L-Lactate Dehydrogenase/blood
Metalloporphyrins/ pharmacology
Mice, Inbred C57BL
Mice, Knockout
Nitric Oxide Synthase/antagonists & inhibitors/genetics/metabolism
Nitric Oxide Synthase Type II
Nitric Oxide Synthase Type III
Oxidative Stress/drug effects/genetics
Peroxynitrous Acid/ metabolism
Survival Rate
Antibiotics, Antineoplastic
Creatine Kinase/metabolism
Doxorubicin
Enzyme Activation/drug effects
Heart Failure/ chemically induced/pathology/physiopathology
Hemodynamics/drug effects
L-Lactate Dehydrogenase/metabolism
Metalloendopeptidases/metabolism
Poly(ADP-ribose) Polymerases/ genetics/ metabolism
Survival Analysis
Ventricular Function, Left/genetics
Apoptosis
Benzamides/ pharmacology
Caspases/metabolism
Cells, Cultured
DNA Damage/drug effects
DNA Fragmentation/drug effects
Enzyme Activation/drug effects/physiology
Enzyme Inhibitors/ pharmacology
Mitochondria/ drug effects
Nitrates
Nitrites/toxicity
Nitrogen Oxides/ toxicity
Poly(ADP-ribose) Polymerases/ antagonists & inhibitors/metabolism
Protective Agents/ pharmacology
Thymus Gland/cytology/ drug effects
Tyrosine
Megjelenés:Oncology reports. - 11 : 2 (2004), p. 505-508. -
További szerzők:Mabley, Jon G. Liaudet, Lucas Virág László (1965-) (biokémikus, sejtbiológus, farmakológus) Szabó Csaba Pacher Pál
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

11.

001-es BibID:BIBFORM095628
Első szerző:Bárány Beatrix (PhD hallgató)
Cím:Nutritional assessment among patients with cervical cancer and controls / Bárány Beatrix, Póka Róbert
Dátum:2020
ISSN:0392-2936
Megjegyzések:Summary The present study aims to acquire an insight into the nutrition of cervical cancer patients, to assess food consumption pattern in patients and controls, to identify assess dietary deficiencies in women recently diagnosed with cervical cancer compared to controls, and to investigate dietary changes during treatment. This study was conducted among 65 patients diagnosed with cervical cancer, and 170 controls, at the Division of Gynecological Oncology of the University of Debrecen, in Hungary. The authors used the food frequency questionnaire and the three-day diet record to assess nutrition. Based on the results, the consumption frequency of vegetables and legumes was significantly lower among the cases. Patients' dietary intake of vitamin D, C, and folate was significantly lower at the time of diagnosis, compared to controls. Nutrient intake is similarly insufficient among patients during the treatment. The present results show nutritional problems among cervical cancer patients and further research is required.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Cervical cancer
Nutrition survey
Nutrient intake
Food consumption
Megjelenés:European Journal Of Gynaecological Oncology. - 41 : 1 (2020), p. 23-29. -
További szerzők:Póka Róbert (1960-) (szülész-nőgyógyász, klinikai onkológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

12.

001-es BibID:BIBFORM049348
035-os BibID:(PMID)23955198 (Scopus)84896034980 (WOS)000329356600017
Első szerző:Bárdi Edit (csecsemő- és gyermekgyógyász)
Cím:Value of FDG-PET/CT Examinations in Different Cancers of Children, Focusing on Lymphomas / Edit Bárdi, Mónika Csóka, Ildikó Garai, István Szegedi, Judit Müller, Tamás Györke, Kornélia Kajáry, Karolina Nemes, Csongor Kiss, Gábor Kovács
Dátum:2014
ISSN:1219-4956 1532-2807
Megjegyzések:The aim of the study was to assess sensitivity and specificity of FDG-PET/CT in different forms of childhood cancer. We retrospectively evaluated the results dedicated of 162 FDG-PET/CT examinations of 86 children treated with: Hodgkin lymphoma (HL; n=31), non-Hodgkin lymphoma (NHL; n=30) and other high grade solid tumors (n=25). Patients were admitted and treated in two departments of pediatric hematology and oncology in Hungary. FDG-PET/CT was performed for staging (n=25) and for posttreatment evaluation (n=137). Imaging was performed in three FDG-PET/CT Laboratories, using dedicated PET/CT scanners. False positive results were defined as resolution or absence of disease progression over at least 1 year on FDG-PET/CT scans without any intervention. In some cases histopathological evaluation of suspicious lesions was performed. Fals negative results were defined as negative FDG-PET/CT results in case of active malignancy. Positive predictive values (PPV) and negative predictive values (NPV) were calculated. NPV was 100 %. The highest PPV was observed in high grade solid tumors (81 %), followed by HL (65 %) and NHL (61 %). There was a major difference of PPV in different histological types of HL (50 % in HL of mixed-cellularity subtype, 90 % in nodular sclerosing, and 100 % in lymphocyte-rich and lymphocyte depleted HL). We treated one patient with nodular lymphocyte predominant HL, who had 5 false positive FDG-PET/CT results. PPV of T- and B-lineage NHL were similar (60 % and 62 %, respectively). We observed an interesting difference of PPV in different stages of HL and NHL. In HL PPV was higher in early than in advanced disease forms: 66 % in stage II HL and 60 % in stage III HL, whereas there was an inverse relationship between PPV and disease stages in NHL 0 % in stage I and II patients, 67 % in stage III and 100 % in stage IV patients. PPV was lower in males (54 %) than in females (65 %). PPV were 64 % vs. 58 % in patients under vs. over 10 years of age. Negative FDG-PET/CT results during follow-up reliably predict the absence of malignancy. Positive FDG-PET/CT scan results in general have a low PPV. The relatively high PPV in patients with histologically proven high grade solid tumors, advanced stages of NHL and with nodular sclerosing, lymphocyte-rich and lymphocyte depleted subtypes of HL warrant a confirmation by biopsy, whereas the watch-and-wait approach can be used in other forms of childhood cancer patients with a positive FDG-PET/CT result in course of follow-up examinations.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
FDG-PET/CT
Megjelenés:Pathology Oncology Research. - 20 : 1 (2014), p. 139-143. -
További szerzők:Csóka Mónika Garai Ildikó (1966-) (radiológus) Szegedi István (1969-) (hematológus, onkológus, nefrológus) Müller Judit Györke Tamás Kajáry Kornélia Nemes Karolina Kiss Csongor (1956-) (hematológus, onkológus) Kovács Gábor (gyermekhaematológus Budapest)
Pályázati támogatás:TÁMOP-4.2.2.A-11/1/KONV-2012-0025
TÁMOP
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 2 3 4 5 6 7 8 9 10  ... Utolsó
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.